 Introduction: The TAILOR study in living donor kidney transplantation demonstrated a 98 one year patient and graft survival and 91 and 83 at 5 years with rejection-free patients in 93. The cumulative dose of r ATG thymoglobulin was 5.29 mg kg with 3 adverse effects and almost 50 steroid free at 12 months. Others have explored the benefit of low doses of r ATG thymoglobulin 3-5 mg kg against Basiliximab in low-risk population and demonstrated in living donor recipients with 8 year follow-up similar survival rates with a lower BPAR rate in rATG thymoglobulin p 0.05 and better serum creatinine in 3 and 5 years. The aim of the study was to demonstrate that low dose 3 mgkg total rATG thymoglobulin has similar efficacy delayed graft function, slow graft function, biopsy proven acute rejection episodes, infections, hospitalizations, adverse events, graft loss and death than Basiliximab induction. 